Skip to main content
Year archive

RELIEF Therapeutics Holding AG — 2020 filings

All 17 regulatory filings released by RELIEF Therapeutics Holding AG (RLF) in 2020, sourced directly from the official regulator.

17 Filings
2020 Period
2020 filings (17)
Filing Released Lang
Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Environmental & Social Information
2020-12-30 English
Relief Appoints Chris L.J.J. Stijnen as Chief Commercial Officer
Board/Management Information
2020-12-21 English
Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority
AGM Information
2020-12-18 English
Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Regulatory Filings
2020-12-07 English
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100(TM) (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients
Regulatory Filings
2020-11-24 English
Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG
AGM Information
2020-11-23 English
Relief Selects CRO and CDMO for RLF-100TM in Europe
Regulatory Filings
2020-11-18 English
Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Legal Proceedings Report
2020-11-13 English
Relief Therapeutics and NeuroRx announce continuation of RLF-100(TM) trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020
Regulatory Filings
2020-11-05 English
Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team
Board/Management Information
2020-11-04 English
Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
Board/Management Information
2020-10-08 English
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100(TM) (aviptadil)
Regulatory Filings
2020-09-30 English
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM
Capital/Financing Update
2020-09-28 English
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
Regulatory Filings
2020-09-21 English
Relief Reports Half-Year 2020 Results
Report Publication Announcement H1 2020
2020-09-15 English
Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer
Board/Management Information
2020-09-04 English
Relief Announces Successful Up-listing from OTC Pink to OTCQB and Capital Increase from its Share Subscription Facility with GEM
Share Issue/Capital Change
2020-08-31 English